Dr. Reddy’s marks entry into Biosimilar Immuno-Oncology in India with launch of NIVORZ®

image credit- freepik

Hyderabad-based Dr. Reddy’s Laboratories has announced the launch of NIVORZ^® (Nivolumab Biosimilar) in India. NIVORZ^® is a biosimilar to Opdivo® (nivolumab),  a fully human monoclonal antibody that targets the PD-1 (Programmed Death-1) immune checkpoint, helping restore the immune system's ability to identify and fight cancer cells. 

The launch represents a significant milestone for Dr. Reddy’s, with NIVORZ^® marking its entry into biosimilar immuno-oncology in India. Developed and manufactured entirely in-house at Dr. Reddy's biologics facility in Bachupally, Hyderabad, it reflects the company’s end-to-end capabilities across the biosimilar value chain, from development through commercialisation.

Oncology remains an important focus area for Dr. Reddy's. The launch of NIVORZ^® further strengthens the company's oncology portfolio and expands its presence in immuno-oncology. The Immuno-Oncology market in India is estimated at approximately Rs 3,900 crore in 2025 and is predominantly driven by checkpoint inhibitors such as nivolumab, pembrolizumab and toripalimab.

Access to immuno-oncology therapies remains a challenge for many patients due to the cost and duration of treatment. Through NIVORZ^®, Dr. Reddy's aims to broaden access to high-quality nivolumab therapy with an affordable biosimilar option for eligible patients.

Based on the clinical development programme, NIVORZ^® has been approved in India by the Drugs Controller General of India (DCGI).